BACKGROUND AND OBJECTIVES: Neoadjuvant chemotherapy is applied to improve the prognosis of patients with advanced gastric cancer. However, only a major histopathological response will provide a benefit. Recent studies suggest that [(18)F]-fluorodeoxyglucose-positron-emission-tomography (FDG-PET) correlates with response and survival in patients with gastroesophageal adenocarcinomas undergoing neoadjuvant chemotherapy. We evaluated the potential of FDG-PET for the assessment of response and prognosis in the multimodality treatment of gastric cancer. METHODS: Study patients were recruited from a prospective observation trial. Forty two patients with advanced gastric cancer received neoadjuvant chemotherapy and subsequently 40 patients underwent standardized gastrectomy (2 patients with tumor progression had therapy limited to palliative chemotherapy without surgery). Histomorphologic regression was defined as major response when resected specimens contained <10% vital tumor cells. FDG-PET was performed before and 2 weeks after the end of neoadjuvant chemotherapy with assessment of the intratumoral FDG-uptake [pre-treatment standardized uptake value (SUV1); post-treatment SUV (SUV2); percentage change (SUVDelta%)]. RESULTS: Histomorphological tumor regression was confirmed as a prognostic factor (P = 0.039). No significant correlations between SUV1, SUV2, or SUVDelta% and response or prognosis were found. CONCLUSION: FDG-PET seems not to be an imaging system that effectively characterizes major/minor response and survival in patients with gastric cancer following multimodality treatment. (c) 2010 Wiley-Liss, Inc.
BACKGROUND AND OBJECTIVES: Neoadjuvant chemotherapy is applied to improve the prognosis of patients with advanced gastric cancer. However, only a major histopathological response will provide a benefit. Recent studies suggest that [(18)F]-fluorodeoxyglucose-positron-emission-tomography (FDG-PET) correlates with response and survival in patients with gastroesophageal adenocarcinomas undergoing neoadjuvant chemotherapy. We evaluated the potential of FDG-PET for the assessment of response and prognosis in the multimodality treatment of gastric cancer. METHODS: Study patients were recruited from a prospective observation trial. Forty two patients with advanced gastric cancer received neoadjuvant chemotherapy and subsequently 40 patients underwent standardized gastrectomy (2 patients with tumor progression had therapy limited to palliative chemotherapy without surgery). Histomorphologic regression was defined as major response when resected specimens contained <10% vital tumor cells. FDG-PET was performed before and 2 weeks after the end of neoadjuvant chemotherapy with assessment of the intratumoral FDG-uptake [pre-treatment standardized uptake value (SUV1); post-treatment SUV (SUV2); percentage change (SUVDelta%)]. RESULTS: Histomorphological tumor regression was confirmed as a prognostic factor (P = 0.039). No significant correlations between SUV1, SUV2, or SUVDelta% and response or prognosis were found. CONCLUSION:FDG-PET seems not to be an imaging system that effectively characterizes major/minor response and survival in patients with gastric cancer following multimodality treatment. (c) 2010 Wiley-Liss, Inc.
Authors: Nikolaos Charalampakis; Lianchun Xiao; Elena Elimova; Roopma Wadhwa; Hironori Shiozaki; Yusuke Shimodaira; Mariela A Blum; Venkatram Planjery; Jane E Rogers; Aurelio Matamoros; Tara Sagebiel; Prajnan Das; Jeffrey H Lee; Manoop S Bhutani; Brian Weston; Jeannelyn S Estrella; Brian D Badgwell; Jaffer A Ajani Journal: Oncology Date: 2015-09-23 Impact factor: 2.935
Authors: Florian Huemer; Stefan Hecht; Bernhard Scharinger; Verena Schlintl; Gabriel Rinnerthaler; Konstantin Schlick; Ronald Heregger; Thomas Melchardt; Angela Wimmer; Iris Mühlbacher; Oliver Owen Koch; Daniel Neureiter; Eckhard Klieser; Sara Seyedinia; Mohsen Beheshti; Richard Greil; Lukas Weiss Journal: J Cancer Res Clin Oncol Date: 2022-07-21 Impact factor: 4.322
Authors: Stefan Wiehr; Oliver von Ahsen; Lars Röse; Andre Mueller; Julia G Mannheim; Valerie Honndorf; Damaris Kukuk; Gerald Reischl; Bernd J Pichler Journal: Mol Imaging Biol Date: 2013-04 Impact factor: 3.488
Authors: Varun Manoharan; Soon Lee; Shanley Chong; June Yap; Nick Coupe; Robert Wilson; Neil Merrett; Weng Ng; Michael Lin Journal: Ann Nucl Med Date: 2017-03-15 Impact factor: 2.668